*** another announcement ***

Enters commercialisation agmt for insulin in Indonesia

Announced by: SCIGEN LIMITED (SIE)
Announced on: 07/02/2003 10:44:20
Part: A
Words: 237
Status: Market sensitive (Y)



--------------------------------------------------------------------------------

SCIGEN LIMITED 2003-02-07 ASX-SIGNAL-G

HOMEX - Sydney

+++++++++++++++++++++++++
MEDIA RELEASE

SCIGEN ENTERS COMMERCIALISATION AGREEMENT FOR INSULIN IN INDONESIA

The Directors of SciGen Limited ("SciGen") announced today that the
company has entered into a commercialisation agreement with PT Kalbe
Farma Tbk ("Kalbe") for the marketing, sale and distribution of
SciGen's human insulin throughout Indonesia.

The agreement is on a non-exclusive basis for 10 years which allows
SciGen to engage other distribution partners in Indonesia if it so
wishes.

Kalbe is a publicly listed company in Indonesia with a current market
capitalisation of US$117 million and employs over 5,000 staff.

Kalbe is also a licensee for other major pharmaceutical companies
such as Bristol Myers, Baxter, Pfizer and Schering Plough. Kalbe's
annual pharmaceutical sales are in excess of US$280 million.

The Agreement with Kalbe is expected to generate over US$1.5 million
dollars in revenues over the next three years with minimum order
provisions. It is anticipated that registration of SciGen's insulin
in Indonesia will take about 9 months.

The relationship that has been formed with Kalbe has the potential to
cover other products in SciGen's portfolio in due course.

The agreement between SciGen and Kalbe is another example of SciGen's
ability to work in the Asia Pacific Region to establish partnerships
in order to maximise sales and marketing opportunities for SciGen's
portfolio of products.